CENTENNIAL, Colo.--(BUSINESS WIRE)--Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced today that the principal researcher for its ICA-1 compound, Dr. Mildred Acevede-Duncan, will present an abstract of the ICA-1 compound at the American Association for Cancer Research (“AACR”) Annual Meeting in San Diego, California on April 14, 2008. The Company’s abstract has been scheduled for presentation in a Poster Session at the 2008 AACR Annual Meeting in San Diego and will be published in the 2008 Proceedings of the American Association for Cancer Research.
